华泰柏瑞生物医药混合C(010031)利润分配表
|
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
收入 |
-31,427,411.14 |
-38,397,765.41 |
-27,723,708.26 |
-24,276,373.28 |
利息合计 |
253,933.19 |
146,480.47 |
593,314.21 |
301,744.46 |
其中:存款利息收入 |
214,195.60 |
106,742.88 |
593,314.21 |
301,744.46 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
39,737.59 |
39,737.59 |
- |
- |
投资收益合计 |
-71,752,076.56 |
-61,349,745.20 |
-7,748,744.65 |
12,410,667.38 |
其中:股票投资收益 |
-77,720,529.51 |
-65,222,093.61 |
-10,742,430.04 |
9,783,714.99 |
基金投资收益 |
- |
- |
- |
- |
债券投资收益 |
240,476.80 |
71,696.88 |
- |
- |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
- |
- |
- |
股利收益 |
5,727,976.15 |
3,800,651.53 |
2,993,685.39 |
2,626,952.39 |
基金分红收益收益 |
- |
- |
- |
- |
公允价值变动收益 |
39,807,807.20 |
22,766,370.57 |
-20,837,426.47 |
-37,146,264.84 |
其他收入 |
262,925.03 |
39,128.75 |
269,148.65 |
157,479.72 |
费用 |
6,783,855.37 |
3,158,208.42 |
8,603,483.56 |
4,953,719.29 |
管理人报酬 |
5,380,452.69 |
2,517,800.80 |
7,012,854.80 |
4,060,849.42 |
基金托管费 |
896,742.13 |
419,633.48 |
1,168,809.04 |
676,808.18 |
销售服务费 |
288,115.93 |
100,100.37 |
183,843.18 |
97,407.26 |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
218,541.60 |
120,673.57 |
237,976.54 |
118,654.43 |
利润总额 |
-38,211,266.51 |
-41,555,973.83 |
-36,327,191.82 |
-29,230,092.57 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年